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Herpes simplexa b s t r a c t
Development of a vaccine against herpes simplex virus type 2 (HSV-2), a life-long sexually-transmitted
infection (STI), would be a major step forward in improving global sexual and reproductive health. In this
review, we identified published literature of dynamic mathematical models assessing the impact of either
prophylactic or therapeutic HSV-2 vaccination at the population level. We compared each study’s model
structure and assumptions as well as predicted vaccination impact. We examined possible causes of
heterogeneity across model predictions, key gaps, and the implications of these findings for future
modelling efforts. Only eight modelling studies have assessed the potential public health impact of
HSV-2 vaccination, with the majority focusing on impact of prophylactic vaccines. The studies showed
that even an imperfect prophylactic HSV-2 vaccine could have an important public health impact on
HSV-2 incidence, and could also impact HIV indirectly in high HIV prevalence settings. Therapeutic vac-
cines also may provide public health benefits, though they have been explored less extensively. However,
there was substantial variation in predicted population-level impact for both types of vaccine, reflecting
differences in assumptions between model scenarios. Importantly, many models did not account for
heterogeneity in infection rates such as by age, sex and sexual activity. Future modelling work to inform
decisions on HSV vaccine development and implementation should consider cost-effectiveness, account
for additional HSV-2 sequelae such as neonatal transmission, and model greater heterogeneity in infec-
tion rates between individuals, more realistic vaccine deployment, and more thorough sensitivity and
uncertainty analyses.
Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
Development of a vaccine against herpes simplex virus type 2
(HSV-2), a life-long sexually-transmitted infection (STI), would
critically improve global sexual and reproductive health. In 2012,
417 million people aged 15–49 years were estimated to be infected
with HSV-2, 64% of whom were women [1]. HSV-2 infection can
cause recurrent painful genital lesions and is often associated with
negative psychosocial effects such as shame, anxiety, and
depression [2,3]. Although neonatal herpes from mother-to-childtransmission is rare, it has high morbidity and mortality [4]. In
addition, evidence suggests that HSV-2 infection increases suscep-
tibility to and infectivity with HIV [5–7]. This increased HIV sus-
ceptibility is likely due to increases in activated CD4+ HIV target
cells and breaks in the genital mucosa during active HSV infection,
which facilitate viral entry. HSV-2 infection correlates with higher
levels of HIV viraemia and therefore infectivity [8–11]. Herpes sim-
plex virus type 1 (HSV-1) is related to HSV-2 and is also a common
lifelong viral infection. Although HSV-1 is usually acquired orally
during childhood, causing orolabial clinical manifestations [12], it
can also be acquired genitally, causing genital ulcers. Genital
HSV-1 infection is usually milder than HSV-2, causing less frequent
recurrences of symptomatic ulceration and viral shedding [13], but
neonatal transmission risk may be higher for HSV-1 than HSV-2 if
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previous HSV-1 infection reduces the risk of symptomatic HSV-2
seroconversion [15].
Antiviral treatment with medications such as acyclovir, famci-
clovir, and valacyclovir can reduce severity and frequency of HSV
genital symptoms [16], and a large trial in high-income countries
showed daily valacyclovir can reduce HSV transmission to sex
partners by 48% [17]. However, treatment is a sub-optimal preven-
tion tool since it cannot cure infection and has incomplete impact
on infectivity, even when taken daily [18]. Though past vaccine
candidates have not achieved desired clinical efficacies [19,20],
advances in adjuvants, our understanding of HSV immunology,
and development of efficacious vaccines against varicella zoster
virus, a closely related alpha-herpesvirus, have led to renewed
interest in HSV vaccine development [21]. Several novel HSV vac-
cine candidates are now in clinical and pre-clinical development,
holding promise for addressing the public health burden of genital
herpes [21,22]. A global roadmap recently outlined critical steps to
facilitate and accelerate STI vaccine development and decision-
making [23]. One of these key steps is to model the potential
impact (i.e., population-level effectiveness and cost-effectiveness)
of vaccination against HSV-2.
Transmission dynamic models (i.e., dynamical models, here
onward) are increasingly used for informing vaccination policies
because they include herd effects, which are needed to evaluate
the population-level impact across multiple vaccination strategies.
Dynamical models can be used at different stages of vaccine devel-
opment [24–28]. Early on, dynamical models can inform invest-
ment cases for vaccine development and guide decision-making
by vaccine developers and funders. Dynamical modeling can also
help determine characteristics a vaccine must have in different set-
tings to maximize improvements in population health. As vaccine
development progresses and safety and efficacy data accumulate
from clinical trials, model-based impact analyses can inform policy
decisions on whether and how to optimally introduce vaccination
in different settings, e.g., clarifying target populations and
implementation strategies given the specific characteristics of the
vaccine and population. Models are also valuable to inform the
design and interpretation of surveillance studies post-vaccination
[29–31].
In 2015 the World Health Organization (WHO) hosted an expert
consultation on HSV-2 vaccine impact modeling [32] to under-
stand what modeling work had already been done, remaining gaps,
and questions and key considerations for future models in order to
inform an investment case for HSV-2 vaccine development and
preferred product characteristics. In preparing for the consultation,
and subsequently to catalyze new modeling efforts to inform HSV-
2 vaccine development, we reviewed the published literature on
mathematical models assessing population-level effectiveness of
HSV-2 vaccination. The objectives of the review were to describe
the models’ structures and assumptions, summarize predicted vac-
cination impact, discuss possible causes of heterogeneity across
model predictions and explore the implications of these findings
for future modeling efforts.2. Methods
We conducted a literature review to identify peer-reviewed
publications of dynamical models of population-level impact of
HSV-2 vaccination. We searched PubMed for literature published
between 1 January 1980 and March 2017, using the following
untagged search terms: ‘(vaccine OR vaccination) AND (HSV OR
herpes simplex) AND (mathematical model OR simulation model
OR individual based model OR agent-based model) NOT (animal).’
We included publications that reported results from dynamicalmodels of HSV-2 vaccination. We excluded publications that solely
used (1) within-host models, (2) static/Markov cohort models, (3)
commentary or review of prior modeling results, or (4) models that
studied HSV-2 transmission dynamics without an intervention, or
only studied other non-vaccine interventions (e.g. HSV-2 antiviral
treatment). The abstract and title of records retrieved from the
search were scanned for relevance. The full texts of potentially-
relevant publications were then reviewed to confirm relevance.
References of included publications were perused to identify addi-
tional relevant publications.
We extracted information describing the key features and
assumptions of each modeling study on: (i) population (demogra-
phy, sexual behavior, setting) and calibration, (ii) HSV-2 natural
history, (iii) vaccine characteristics and vaccination strategy, (iv)
health outcomes modeled to predict impact (e.g., HSV-2 infection,
HIV infection, neonatal infection, economic outcomes) [28]. We
compared predicted epidemiological impact of vaccination using
the most commonly-reported outcome across models (i.e. HSV-2
incidence), which was extracted from the main text, tables, and fig-
ures. Since one study, Newton et al. [33], only presented results on
HSV-2 prevalence, and the model was easy to reproduce, we
recoded it using the same assumptions and parameter values to
derive vaccination impact on HSV-2 incidence for the same scenar-
ios explored in the publication (details of these methods are in
Supplemental materials).3. Results
3.1. Search results
Of the 45 potentially-relevant modeling publications identified,
seven met the inclusion criteria (details in Supplemental Fig. S1).
One additional publication [34] was identified from the reference
lists of included publications [33,35–40]. In total, eight unique
dynamical modeling studies, published between 2000 and 2012,
that assessed the potential population-level impact of HSV-2 vac-
cination, were included in our review [33–40].3.2. Description of model characteristics
Table 1 defines the terminology used to describe vaccine char-
acteristics and vaccination roll-out strategies. Table 2, Figs. 1 and
2, and Supplemental Table S1 summarize the characteristics of
the different modeling studies. Seven studies used deterministic
compartmental models and one used a stochastic individual-
based model [38].
(i) Population and calibration
All models represented open populations (i.e. people entering
and leaving the population) that were assumed to be sexually
active for various durations ranging from 9 years (representing
only young adults [33]) to 35 years (representing younger and
older adults [35,39]). Five models [33,34,36,37,39] did not distin-
guish between sexes (i.e., females and males were combined)
whereas three models explicitly represented males and females
[35,38,40] (Fig. 1, Table 2). Only one model was age structured
[38], and three models included heterogeneous sexual activity
classes [35,38,39]. Models either represented settings in sub-
Saharan Africa (SSA) [38,39], North America [35–37,40], or unspec-
ified generic settings [33,34]. Baseline HSV-2 prevalence was
assumed to be low only (15–25%) (N = 4) [34,35,37,40], high only
(35–60%) (N = 2) [33,39], or both (N = 2) [36,38]. Model calibration
was minimal. Freeman et al. manually fitted the model to setting-
specific demographic characteristics and age-stratified HSV-2 and
Table 1
Glossary of vaccine and vaccination terms used to describe models (based on Boily et al. (2012)[28]).
Term Definition
Vaccine types
Prophylactic vaccine A vaccine given before acquiring infection, primarily intended to prevent infection of the vaccinated host. Some
prophylactic vaccines may also reduce disease manifestations and infectivity during breakthrough infections, i.e.,
those occurring despite vaccination.
Therapeutic vaccine A vaccine given after acquiring infection, primarily intended to improve disease outcomes (progression, severity,
occurrence), akin to treatment effects. Therapeutic vaccines may also reduce infectivity.
Vaccine characteristics and vaccine efficacies (VE)
Take – effectively vaccinated The probability that a vaccinated person will develop an adequate immune response (i.e., be effectively vaccinated)
that can protect them fully (perfect sterilizing immunity) or partially against infection or disease.
Susceptibility effects –reduction in susceptibility
(prophylactic vaccine)
VEStake: Take for a prophylactic vaccine –% effectively protected against infection.
VES: The percentage reduction in the risk of infection upon exposure among people effectively vaccinated. For
example, VES = 100% or 50% means that an individual effectively vaccinated (i.e., among whom the vaccine
‘‘takes”) has 0% or 50% chance of becoming infected per exposure, respectively.
Breakthrough effects (prophylactic vaccine) Infectivity and/or pathogenicity effects (described below) conferred by a prophylactic vaccine should a vaccinated
host subsequently become infected. Not all prophylactic vaccines confer breakthrough effects.
Pathogenicity effects – reduction in disease
progression or severity or adverse events
(prophylactic or therapeutic vaccines)
VEPtake: Take for a therapeutic vaccine –% effectively protected against pathogenicity.
VER: Percentage reduction in the frequency of symptomatic and/or asymptomatic reactivation (shedding) in
effectively vaccinated infected individuals.
VEL: Percentage reduction in the duration of symptomatic and/or asymptomatic reactivation (shedding) in
effectively vaccinated infected individuals.
VEU: Percentage reduction in the frequency or duration of ulcerative disease only (no shedding reduction).
Note: Decreased frequency or duration of reactivation may indirectly reduce transmission by reducing the
number of days with viral shedding, viral load, or ulcers, depending on the relationship between disease,
shedding and transmission.
Infectivity effects – reduction in infectivity
(prophylactic or therapeutic vaccine)
VEItake: Take for a therapeutic vaccine –% effectively protected against infectivity.VEI: Percentage reduction in the
infectivity of effectively vaccinated but infected individuals to their partners, due to a reduction in viral shedding.
For example, when VEI = 100% or 75%, an effectively vaccinated infected individual is not or only 1/4 as infectious
as an unvaccinated infected individual, respectively. Note: the reduction can be conferred at specific stages or
across all stages.
Duration of effects – waning Lifetime: Efficacy remains constant for the lifetime of the vaccinated individual (i.e., no waning).
Finite: Efficacy wanes over time (e.g., after 5, or 20 years), and may necessitate booster vaccination.
Vaccination roll-out strategies
Routine vaccination Vaccination of a specific target population repeated routinely (e.g., each year).
Catch-up vaccination Vaccination of individuals who may have been missed or are typically not included in routine vaccination (e.g.,
older age-cohorts, specific risk groups, gender). Catch-up vaccination campaigns are often implemented for a
limited period of time.
Booster vaccination Vaccination given after an initial vaccination course, to counteract waning vaccine effects. Boosters are most
relevant if individuals remain at risk for infection past the period of waning vaccine effects.
Mass vaccination Vaccination of a large fraction of the population in a very short period of time.
Target population The population that we aim to vaccinate (e.g., girls, sexually-active adults, pregnant women, newly HSV-2
positive people).
Gender-neutral Vaccination of both men and women.
Uptake Fraction of target population vaccinated each year. It may be represented as a rate in models
Coverage Cumulative fraction of the population that is vaccinated (effectively or not) after a fixed time period; may also be
sub-group specific. Note: When the take is <100%, the coverage and the fraction of individuals effectively
vaccinated differ.
Vaccination scenarios modeled (types of vaccine effects modeled in Garnett et al. (2004) and Freeman et al. (2009))
Sc1 Vaccine affects symptom frequency only (no reduction in susceptibility or infectivity).
Sc2 Vaccine affects symptom frequency and symptomatic infectivity.
Sc3 Vaccine affects symptom frequency and all infectivity (symptomatic and asymptomatic).
Sc4 Vaccine affects susceptibility only.
Sc5 Vaccine affects susceptibility, symptom frequency, and symptomatic shedding/infectivity.
Sc6 Vaccine affects susceptibility, symptom frequency, and all shedding/infectivity.
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each setting (Cotonou, Benin, and Kisumu, Kenya). Schwartz et al.
simultaneously varied and identified multiple parameter values
reproducing the desired HSV-2 prevalence. One study [34] did
not fit to any historical HSV-2 infection pattern. All others manu-
ally fitted models to a single HSV-2 prevalence using a single
parameter set. Six studies assessed vaccination impact assuming
HSV-2 was at or near equilibrium (N = 6) [35–40] while two
assumed HSV-2 was in its initial growth phase (N = 2) [33,34]
although the latter will not be representative of most real-life
settings.
(ii) HSV-2 natural history
Fig. 2 illustrates how each model represented HSV-2 natural
history at the individual level. During initial or primary HSV-2infection, individuals can develop genital ulcers and systemic
symptoms lasting 2–3 weeks. Individuals typically shed high quan-
tities of virus and are likely to be highly infectious during this
phase [41,42]. During initial infection, HSV-2 establishes chronic
infection in the sensory ganglia, where the virus periodically
‘‘reactivates”, resulting in viral transport to the genital mucosa
and HSV-2 replication, shedding, and infectivity. HSV-2 reactiva-
tions can occur with or without accompanying genital lesions.
When lesions occur in the presence of replicating genital HSV, this
is often referred to as a ‘‘recurrence”, ‘‘outbreak” or simply ‘‘symp-
tomatic shedding”; when the virus is present in the genital tract
without accompanying lesions, it is referred to as ‘‘asymptomatic
shedding” [9]. Typically, viral shedding occurs with a higher viral
load during recurrences than asymptomatic shedding [43,44], but
regardless of symptoms, chronic HSV-2 infection alternates
between periods of lower and higher infectivity.
Table 2
Characteristics of the 8 different models (see Fig. 1, Supplement Table S1).
Characteristic No. of
studies
Reference
number (s)
Modelling framework
Deterministic compartmental model 7 [33–37,39,40]
Stochastic individual-based model 1 [38]
Population
Sex: No differentiation between the sexes
(1-sex)
5 [33,34,36,37,39]
Males and females represented separately
(2-sex)
3 [35,38,40]
Duration of sexual activity: Short 4 [33,36,37,40]
Long 6 [34–39]
Age-structured 1 [38]
Heterogeneous sexual activity classes 3 [35,38,39]
Setting: Sub-Saharan Africa 2 [38,39]
North America 4 [35–37,40]
Unspecified 2 [33,34]
HSV-2 prevalence: Low (15–25%) 6 [34–38,40]
High (35–60%) 4 [33,36,38,39]
Model calibration to specific setting: None 1 [34]
1 manual fit 4 [33,35,39,40]
2 manual fits 1 [38]
Sensitivity analysis 2 [36,37]
HSV-2 natural history
Initial infection explicitly modeled 4 [33,35,38,39]
Recurrent heterogeneous infectivity
stages (i.e., reactivation = symptomatic
and/or asymptomatic shedding)
7a [33–39]
Recurrence of symptoms reduces sexual
activity
1 [35]
Symptoms/reactivation frequency
declines with infection time
2 [35,38]
HSV-2 treatment or HIV treatment 0 –
Vaccine characteristics
Therapeutic vaccine 2 [33,37]
Prophylactic vaccine (with or without
breakthrough effects)
7 [33–36,38–40]
Duration of vaccine effects: Lifelong 5 [33,35,38–40]
Finite [34,36–38]
Target population
Female-only 3 [35,38,40]
Gender neutral 7 [33–39]
HSV-2 negative 7b [33–36,38–40]
HSV-2 positive 2 [33,37]
Before sexual debut 6 [34–36,38–40]
After sexual debut 6 [33–35,37–39]
Vaccination strategies  target population
Routine vaccination (with and without
catch-up):Before sexual debut - HSV-2
negative
6 [34–36,38–40]
Sexually active - HSV-2 negative 1 [33]
Sexually active - HSV-2 positive 1 [37]
Mass vaccination: HSV-2 negative 1 [39]
HSV-2 positive 1 [33]
Health outcomes modeled
HSV-2 frequency: Incidence ratec 3 [35,38,39]
Riskd 3 [36,37,39]
Prevalence 6 [33–35,38–40]
HIV-1 incidence 1 [38]
Health economic outcomes 0 –
Neonatal transmission 0 –
a Only Garnett modeled symptomatic and asymptomatic reactivation separately
and a latent (i.e., no shedding) phase.
b Target population in Garnett and Lou also HSV-1 negative.
c After 10 or 30 years.
d Cumulative incidence over ten years.
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referred to as ‘‘primary” infection; subsequent stages of infection
with low or no infectivity were referred to as ‘‘asymptomatic”,
‘‘quiescent” or ‘‘latent” periods, and stages with increased viral
shedding and higher infectivity as ‘‘reactivation” or ‘‘recurrence”.The terminology used in these epidemic models sometimes dif-
fered from that used in the clinical literature. For example, in the
clinical literature, primary infection is sometimes defined as infec-
tion with one HSV type among individuals without pre-existing
infection with the other type. Moreover, clinically speaking,
‘‘asymptomatic” periods may or may not include shedding of virus
at levels sufficient for sexual transmission. Nevertheless, the criti-
cal feature is how low and high infectivity states were modeled. All
but one model [40] represented long periods of low [33–35,38] (or
even zero [35–37,39]) infectivity and shorter periods of higher
infectivity due to reactivation (Fig. 2). Two studies reflected that
the frequency of symptoms and reactivation decay with time since
infection [35,38]. Only one study assumed that sexual activity was
reduced during symptomatic recurrences [35].
HSV-1 has interactions with HSV-2 that may influence HSV-2
transmission dynamics and vaccination impact, e.g., if HSV-2 vac-
cination also protects against HSV-1, if it protects differentially
among people infected with HSV-1, or if HSV-1 alters the natural
history of HSV-2 and vice versa. None of the models dynamically
modeled co-circulating HSV-1 and HSV-2 infections. However,
two studies modeled HSV-1 statically by assuming that a constant
population fraction was HSV-1 infected [35,40], in order to reflect
the results of an early vaccine trial showing that vaccination was
only effective among HSV-1 negative women [19]. Only one publi-
cation modeled co-circulating HSV-2 and HIV infections [38]
(Fig. 1, Table 2), assuming that HSV-2 increased susceptibility to
and infectivity with HIV during initial HSV-2 infection and reacti-
vation episodes and estimated the number of HIV infections
prevented by HSV-2 vaccination. Importantly, none of the models
accounted for HSV-2 treatment.
(iii) Vaccine characteristics and vaccination strategy
Vaccines may be broadly categorized as either (i) prophylactic,
if they are administered to susceptible individuals primarily to pre-
vent infection (they may also provide ‘‘therapeutic” benefits fol-
lowing breakthrough infections), or (ii) therapeutic, if they are
administered after infection to ‘‘treat” or ‘‘modify” infection by
alleviating symptoms and/or reducing shedding and infectivity.
Only one publication explicitly modeled therapeutic vaccines, with
pathogenesis and infectivity effects included [37], though another
[33] mimicked a therapeutic vaccine by assuming that when the
vaccination program starts all past and future HSV-2 infected
individuals immediately have reduced infectivity (akin to mass
vaccination of prevalent cases + routine vaccination of all future
incident cases) (Fig. 1). Seven publications modeled a prophylactic
vaccine, either with (N = 5) [34–36,38,39] or without (N = 2)
[33,40] breakthrough effects reducing subsequent infectivity and/or
pathogenicity (Figs. 1 and 2, Table 2, Supplement Table S1). Vaccine
effect durations were either finite (5, 10, or 15 years) [34,36–38]
or lifelong [33,35,38–40] (Table 2). Vaccination roll-out strategies
modeled included mass vaccination [33,39] and routine vaccina-
tion with [34,35,38] or without [33,35–40] catch-up of the target
population, which was either individuals before sexual debut
[34–36,38–40], already sexually active [33–35,37,38], and HSV-2
negative [33–36,38–40] or HSV-2 positive [33,37] (Fig. 1, Table 2).
All models except one [40] explored vaccination of both sexes and
three studies explored female-only vaccination [35,38,40].
(iv) Outcomes modeled
Most models reported the population-level effectiveness of vac-
cination as the relative reduction in HSV-2 incidence rate after 10
or 30 years or in cumulative incidence over 10 years (i.e., infection
risk) in the overall population following the start of theoretical vac-
cination. One [35] reported results for each sex and only one other
Fig. 1. Summary of key model characteristics related to type of vaccine, vaccination strategy, target population, setting and outcomes. Additional details found in
Supplemental Table S1, Figs. 2 and 3. The prophylactic and therapeutic vaccine studies focus vaccination on HSV-2 negative and positive people, respectively. 1-sex models
combine males and females; 2-sex models represent females and males separately, allowing for vaccination of one or both sexes. A sexually active target population refers to
vaccination of people who are already having sex; a sexual debut target population refers to vaccination of people before they become sexually active.
7400 I.H. Spicknall et al. / Vaccine 37 (2019) 7396–7407[38] predicted reductions in HIV incidence following prophylactic
HSV-2 vaccination. No publications considered neonatal or any
health economic outcomes (Table 2). Because the analyses of two
publications [34,40] primarily focused on eradication thresholds,
and mostly made predictions after 250 or 1000 years, they were
excluded from our comparisons across models in the next section
(Supplemental Table S1).
4. Summary of population-level effectiveness predictions of
vaccination
Fig. 3 and Supplemental Table S1 summarize model results for
different sets of assumptions on vaccine characteristics, vaccina-
tion strategies, target population and uptake explored across mod-
els. These studies suggest that HSV-2 vaccination could reduce
HSV-2 incidence rate by as little as 5% after 30 years or up to
88% after 10 years. Not surprisingly, studies that explored a wider
range of assumptions and vaccine parameter values (Schwartz
et al. (2005, 2007) [36,37], Freeman et al. (2009) [38] produced
wider ranges of predictions.
The earliest model by Newton et al. (2000) [33] optimistically
predicted 62% and 81% reduction in HSV-2 incidence rate 10 years
after routine vaccination of 1% and 2% of sexually-active adoles-
cents monthly, achieving coverage of 43% and 61% after 10 years,
respectively. They predicted even larger reduction (74% or 91%
HSV-2 incidence reduction after 10 years) with a therapeutic-like
mass vaccination scenario assuming that the infectivity of all
HSV-2 infected individuals would be immediately reduced by
50% or 75%.
In Garnett et al. (2004) [35], the incidence reduction among
women or men ranged between 5% and 40% 30 years after rou-
tine (50% of girls at sexual debut) and catch-up (5% adult womenannually) vaccination across six scenarios and three efficacies
(low, medium, high), where the vaccine was assumed to reduce:
(Sc1) symptom frequency only (no reduction in infectivity), (Sc2)
symptom frequency and symptomatic infectivity, (Sc3) symptom
frequency and all infectivity (symptomatic and asymptomatic),
(Sc4) susceptibility only, (Sc5) susceptibility, symptom frequency,
and symptomatic shedding/infectivity, (Sc6) susceptibility, symp-
tom frequency, and all shedding/infectivity (Fig. 3). Fig. 4 shows
additional results by sex for scenarios Sc1-6. Interestingly, the
population-level effectiveness was only marginally higher in
women than men, even if vaccination was only effective in women,
because men benefit from herd effects. Incidence reduction was
larger among men only when they directly benefited from the
reduction in infectivity of vaccinated women (Sc3). HSV-2 inci-
dence reduction was higher for a vaccine with breakthrough and
susceptibility effects (Sc5 or 6), than with susceptibility effects
only (Sc4), especially when both symptomatic and asymptomatic
infectivity were decreased (Sc6). In addition, the population-level
effectiveness of a vaccine with infectivity (symptomatic and
asymptomatic) and pathogenicity effects (Sc3) was larger than
with susceptibility effects only (Sc4). Overall, incidence reductions
were modest, despite being measured 30 years after vaccination
began, primarily because the vaccine was assumed to only be
effective among women uninfected with HSV-1 (assumed HSV-1
prevalence is 60%) (Fig. 4). In scenario 6, the population-level effec-
tiveness nearly doubled when the vaccine was also effective
among the 40% women who were HSV-1 infected and nearly
tripled when assuming it was effective among 100% of men and
women (Fig. 4). In scenario 1, only symptom frequency was
affected by vaccination, leading to more frequent asymptomatic
periods during which people were more sexually active causing
vaccination to lead to a 5% increase in HSV-2 incidence (Fig. 4).
Fig. 2. Flowchart of HSV-2 natural history, vaccine effects, and efficacy assumptions in each model. Only Lou et al. (2012) in (F) does not represent reactivation episodes of
high infectivity through the life-course of HSV-2 infection. Otherwise, all other models represent reactivation periods associated with increased viral shedding and infectivity
and asymptomatic or latent periods associated with low or no infectivity. Panels (B) and (G) refer to specific scenarios defined in the original publications and presented in
Figs. 4** and 5***. Red, orange, and yellow reflect high, medium and low infectivity within a given model. In addition, Garnett et al. (2004) and Freeman et al. (2009) assume
that reactivation frequency declines with time since infection. S – Susceptible; E – Exposed, not infectious. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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population-level effectiveness of gender-neutral prophylactic and
therapeutic vaccination varying several epidemiological factors
(e.g., transmission rate, sexual lifespan, frequency of reactivation,
duration of reactivation), vaccine characteristics (VEtake, VES, VEI,
VER, VEL, duration of effects), and uptake simultaneously. Theirearlier publication [36] predicted relatively modest overall reduc-
tion in cumulative HSV-2 incidence (3–36% over 10 years) follow-
ing prophylactic vaccination considering that they explored high
vaccine efficacies and uptake (Fig. 3). This is partly because they
modeled routine vaccination of cohorts of new sexually-active
cohorts without catch-up, and because they report a reduction in
Fig. 3. Predicted reduction in HSV-2 incidence rate or risk in the overall population (except Garnett, which reports results by sex) by vaccine types – prophylactic, with or
without breakthrough effects, and therapeutic – for the set of vaccine efficacies, duration of effects, target populations and uptake assumptions explored. N – number of sets
of assumptions; Mid-value [low, high] – predicted population-level effectiveness corresponding to the mid [lowest, highest] parameter value (or middle of the interval when
N = 2); F – female vaccination only; M+F or All – gender-neutral vaccination in a 2-sex and 1-sex model, respectively; L – lifelong; HSV-1 – HSV-1 negative; HSV-2+ – HSV-2
positive; (S, I, P) – susceptibility, infectivity, pathogenicity effects; *For Garnett – VE (39,73,88%) reflects the total reduction in symptoms incidence among vaccinated
individuals resulting from the combined susceptibility (VEStake) and pathogenicity (VEPtake) efficacies assumed. Garnett (S), (I, P), and (S, I, P) corresponds to scenarios Sc4, 1–3, and
5–6, respectively, as described in the text and Fig. 4; here the vaccine is effective among only HSV-1 negative women (only 40% of women). Upper and lower bounds in reductions
represent uncertainty in the prediction based on variation of (i) vaccine efficacy only (Garnett), (ii) vaccine uptake only (Newton, Allsalaq), (iii) vaccine efficacy, duration of
vaccine effects, and vaccine uptake (Freeman), and (iv) vaccine efficacy, duration of vaccine effects, vaccine uptake, and HSV natural history (Schwartz).
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incidence rate. In contrast, their later publication [37] predicted a
larger reduction in the 10 year infection risk following therapeutic
vaccination (24–80% over 10 years) despite exploring similar
ranges of therapeutic effects and uptake to their first publication,
and despite the lack of susceptibility effects. This is at least partly
because routine vaccination targeted all HSV-2 infected individu-
als, resulting in a faster increase in coverage than routine vaccina-
tion of susceptibles. The predicted epidemiological impact with the
therapeutic vaccine required that 30–90% of all asymptomatic
HSV-2 positive people be vaccinated each year, which may be
optimistic. Sensitivity analysis suggested that for a prophylactic
vaccine the take (VEStake) the reduction in susceptibility (VES), and
coverage were more important than all other features varied; break-
through effects had negligible impact. For a therapeutic vaccine it
was more important to reduce infectivity (symptomatic and asymp-
tomatic) than to reduce frequency and duration of reactivation epi-
sodes. Duration of sexual activity also influenced results, which may
explain some variation across model predictions that represented
different populations (e.g., younger versus older adults).
Freeman et al. (2009) [38] predicted that prophylactic vaccina-
tion could reduce the HSV-2 incidence rate by 8% to 88% after
10 years of routine vaccination prior to sexual debut with catch-
up among 15–29 year olds for various sets of assumptions varied
across three dimensions: (1) vaccine effects: reduction in suscepti-
bility only (as Garnett et al.’s Sc4), reduction in shedd reactivation
frequency and duration and all infectivity (as Garnett et al.’s Sc3),or both (as Garnett et al.’s Sc6), (2) vaccine characteristics: efficacy,
duration, and 3) vaccine uptake (Fig. 3). Freeman’s results for the
prophylactic vaccine with breakthrough effects only (I,P) were sim-
ilar to the results of Schwartz et al. (2007) [37] for the therapeutic
vaccine (Fig. 3). Fig. 5A shows the influence of catch-up, gender-
neutral or female-only vaccination, and duration of effects on
model predictions, and Fig. S2 shows the incremental impact of
these same features. The incremental impact of catch-up vaccina-
tion is substantial whereas that of gender neutral vaccination
was weaker (Fig. S2). The incremental impact of a prophylactic
vaccine with susceptibility and breakthrough effects was marginal
compared to a vaccine with susceptibility effects only whereas
vaccines with breakthrough or susceptibility effects only were sim-
ilar (Fig. 5A, Fig. S2). In addition, assuming that HIV susceptibility
and infectivity was higher during initial infection and reactivation
episodes (25-fold, 10-fold per sex act), HIV incidence rates were
indirectly reduced by 1 to 31% 10 years after vaccination across
the ranges of assumptions explored. The reduction in overall HIV
incidence was proportional to the reduction in overall HSV-2 inci-
dence (Fig. 5B). However, their results did not include scale-up of
HIV treatment.
Finally, Alsallaq et al. (2010) [39] suggested that HSV-2
prevalence could be reduced substantially by a vaccine that either
reduces the frequency of reactivation episodes by 75% or reduces
susceptibility by 75% plus reactivation frequency by 10% in high
prevalence settings (results not shown). They predicted 21% and
30% HSV-2 cumulative incidence reductions 10 years after
Fig. 4. Predicted reduction in HSV-2 incidence rate after 30 years among males and females for the six scenarios presented in Garnett’s study where the vaccine is assumed to
reduce: Sc1 – symptoms only (no reduction in infectivity), Sc2 – symptoms and symptomatic infectivity, Sc3 – symptoms and all (symptomatic and asymptomatic)
infectivity, Sc4 – susceptibility only, Sc5 – susceptibility, symptoms and symptomatic infectivity, Sc6 – susceptibility, symptoms, and all infectivity among women HSV-1
negative only (only 40% of women), all women (not men), and both men and women. Other assumptions are as described in Fig. 3. Pos – positive, Neg – negative.
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and mass vaccination of 100% sexually active, respectively (VES =
30%, VER = 75%) (Fig. 3). Sensitivity analysis concluded that unless
a prophylactic vaccine has low efficacy against infection, the incre-
mental impact of reducing shedding frequency will be modest in
the short-term, but would increase over time as more break-
through infections occur.5. Discussion
5.1. Summary and limitations
Eight modeling studies have been published to date on the
potential impact of HSV-2 vaccination at a population level. These
studies showed that even an imperfect prophylactic HSV-2 vaccine
could have an important epidemiological impact on HSV-2 inci-
dence, and could potentially impact HIV incidence in high preva-
lence settings as well. For example, in the one study that
modeled both HSV-2 and HIV transmission in sub-Saharan Africa,
a prophylactic vaccine with only 75% efficacy against infection
could reduce HSV-2 incidence by more than 55% after 10 years,
given 50% vaccination coverage of 14 year-olds and catch-up vacci-
nation through age 29, and could also avert about 10% of incident
HIV infections over the same period [38]. Therapeutic vaccines
have been explored less extensively, and comparison with prophy-
lactic vaccine models was difficult given differences in mecha-
nisms, target populations, and delivery strategies, but available
modeling work suggests these vaccines might also have public
health benefits.The available modeling studies have several limitations. First,
most of the models were relatively simple and did not incorporate
heterogeneities of specific settings and populations. Second,
although one study considered the indirect effect of HSV-2 vacci-
nation on HIV infection, none of the models included any other
HSV outcomes in their measures of vaccine impact, such as neona-
tal herpes, the contribution of HSV-1 to morbidity including genital
herpes, or psychosocial burden. Absent from all studies were costs,
both for care and treatment and for vaccination, and thus any
resulting cost-effectiveness analyses. Third, modeling work has
been more limited for therapeutic vaccines, which may be the first
HSV vaccine candidates approved since they are further along in
clinical development [21,22]. Therapeutic vaccines are an emerg-
ing concept in public health which have been studied little to date
in terms of modeling; more research is warranted to fully under-
stand their expected individual and population benefits, and to
whom and how they should be targeted for optimal resource allo-
cation. In addition, the intervention landscape has changed since
these studies were published with scale-up of interventions like
antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP),
and male circumcision for HIV infection, and potentially new
antiviral therapies for HSV on the horizon [45]. No models of vac-
cine impact included any of these competing interventions, which,
depending on the context, could affect vaccine impact.
Finally, studies varied in the degree to which they conducted
appropriate sensitivity and uncertainty analyses, as well as how
they presented results of vaccination impact; as point estimates
only or with uncertainty ranges that reflected uncertainties in
parameter assumptions and/or the ranges of scenarios explored.
When comparing impact across models, we selected the lowest
(a)
(b)
Fig. 5. (A) Predicted reduction in overall HSV-2 incidence rate across selected sets of assumptions presented in Freeman et al. (2009). Vaccination strategies: routine
vaccination at sexual debut with or without catch-up (50% uptake at 5 years), for a vaccine with different efficacies, duration, and effects (Sc3-6 defined in Table 1). (B) Scatter
plot of the expected reduction in overall HIV incidence rate as a function of the overall reduction in HSV-2 incidence following HSV-2 vaccination for various sets of
assumptions (vaccine effects and efficacies, duration of effects = 10 years) assuming 50% uptake. Vaccine effects: Sc4 – reduction in susceptibility only (VEs), Sc3 – reduction
in shedding reactivation frequency and duration and all infectivity (VEI, VER, VEL), Sc6 – both Sc3 and Sc4 (VEs, VEI, VER, VEL). Mid [Low, High] values represent population-
level effectiveness for efficacies of 75% [50%, 90%] as in Fig. 3.
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each publication. However, this means that we may have selected
unrealistically wide bounds for vaccine impact, or conversely,
given an unrealistically precise estimate of predicted vaccine
impact. In addition, we selected predicted change in HSV-2 inci-dence in our model comparison as this was the most common out-
come used by the studies for vaccine impact. However, achieving
protection against new infection, whilst highly desirable of a vac-
cination program, is not necessarily the only way vaccines can be
useful. Indeed, therapeutic vaccines could be primarily employed
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type of therapeutic vaccination program might have limited reach,
depending on its effect on transmission, but might substantially
improve the quality of life of individuals with diagnosed genital
herpes and be cost-effective. Conversely, if it was deployed more
widely among those HSV-2 positive, a therapeutic vaccine might
have substantial impact on population incidence by decreasing
transmission in serodiscordant partners. In this way modeling
could help inform implementation decisions.
Despite these limitations, the evaluated studies yield several
qualitative insights and provide a good foundation on which to
build future modeling work. First, a vaccine does not necessarily
need to have simultaneous effects on susceptibility, disease and
infectiousness to be useful at the population level. Additional
effects likely lead to increased impact, but this depends on relative
efficacy: breakthrough effects of a prophylactic vaccine (i.e., reduc-
tions in infectivity among vaccinated individuals who experience
breakthrough infection) are most important when vaccine suscep-
tibility effects (i.e., efficacy against acquiring infection) are low.
Second, catch-up vaccination appears important in maximizing
vaccine impact. Third, in settings with relatively high HSV-1 preva-
lence, any vaccine needs to work in those already infected with
HSV-1 to be useful at the population level, except for a prophylac-
tic vaccine given to infants. Finally, even if a vaccine is only directly
efficacious in one sex, it could still provide substantial herd immu-
nity effects to the other sex given high enough levels of coverage
and vaccine efficacy. In theory a prophylactic vaccine that works
equally well in both sexes may not need to be used in both sexes
to achieve public health goals; however, many other factors need
to be considered including equity, which are beyond the scope of
this review. Single-sex vaccination was explored in detail in prior
models because an early vaccine trial showed efficacy only in
HSV-1 seronegative women, which may not be relevant for future
vaccines [19]. Overall, our findings show that factors related to vac-
cine deployment strategy (e.g., whether to employ catch-up vacci-
nation) and biological features of the vaccine (e.g., whether the
vaccine is efficacious regardless of HSV-1 status) are likely more
important than whether the vaccine is efficacious for both sexes.
These findings should be validated for a wider range of epidemio-
logical patterns of infection and sexual behavior patterns.
5.2. Conclusions and future directions
Mathematical modeling of the potential impact of HSV-2 vacci-
nation plays an important role in stimulating investment in the
development of HSV vaccines and ensuring preparedness for vacci-
nation programs before a vaccine comes to market. Once public
health leaders have defined goals for HSV-2 prevention programs
[22], mathematical models can help define the conditions in terms
of vaccine cost and strategy likely to achieve these goals for
vaccines with different characteristics, thereby informing vaccine
development and introduction. Such models need to be able to
generate relevant, dependable, and useful results for decision-
makers. Critical to this will be cost-effectiveness analyses, which
in turn require comprehensive, robust estimates of health utility
and disability weights for HSV infection, which are currently lack-
ing. Additional research is needed to provide these estimates. To
fully capture the impact and cost-effectiveness of HSV vaccination,
other disease outcomes directly or indirectly caused by HSV infec-
tion such as HSV-1 disease, neonatal herpes, and HIV, should be
included in models.
Besides conducting cost-effectiveness analyses with a full range
of outcomes, future models could be extended in three ways from
those studied in this review, to make them more useful for
catalyzing vaccine development and investment as well as inform-
ing future public health decision-making. First, they shouldincorporate greater complexity and heterogeneity, such as hetero-
geneous infection rates by age, sex and sexual activity, in order to
resemble more closely transmission dynamics in countries.
Heterogeneity in infection rates is an important determinant of
intervention impact for STIs [46] and failure to accurately take
such heterogeneities into account could lead to over- or underesti-
mation of potential vaccine impact. For example, prior modeling
work examining the impact of HSV-2 suppressive therapy on HIV
transmission concluded that substantial HIV impact is possible
with high coverage and long duration of suppressive therapy
[47], but this depends on sexual mixing patterns and presence or
absence of commercial sex work among other factors [48,49].
However, with more detailed models come greater difficulties in
mathematical tractability and specification, particularly for ordi-
nary differential equation-based models, and these considerations
must also be factored in. Further work to explore the dynamics and
interactions between HSV-1, HSV-2 and HIV, the relationship
between HSV shedding, viral load and infectivity, and the simplest
way to model the natural history of HSV whilst retaining the key
features important to vaccination impact will be critical in inform-
ing development of these more complex models [50].
Second, model exploration should have a stronger focus on sen-
sitivity and uncertainty analysis. Future work should provide
bounds around predictions that fully reflect parameter uncertainty,
which are useful for policy makers in considering whether to make
recommendations about vaccination or require more detailed data
inputs. Models could also explore the multi-dimensional parame-
ter space defined by epidemiological context (e.g., sexual behav-
iors, HSV-2 and HIV prevalence), vaccine characteristics (e.g.,
biological vaccine effects, duration of protection), and vaccination
strategy (e.g., target population, coverage) in greater detail. Such
an exploration could incorporate different epidemiological and
country income-level scenarios as defined by the WHO expert
consultation on HSV-2 vaccine impact modeling [32], to ensure
models are relevant for global decision making. Using a common
modeling framework, such sensitivity analyses could also rank
characteristics in terms of their influence on incidence and inci-
dence reductions in order to prioritize future data collection
efforts.
Third, models should describe and study vaccine candidates and
characteristics most relevant to the existing development pipeline
and current public health needs, and should contain realistic vac-
cine deployment strategies mapped to the vaccine types and char-
acteristics assessed. This is most notably absent for therapeutic
vaccines, which are presently the furthest along in development
with several candidates currently in, or having recently completed,
phase I and II clinical trials (pipeline reviewed elsewhere [22]). Tar-
get populations and vaccine deployment strategies will differ
markedly between prophylactic and therapeutic vaccine programs;
care should be taken to simulate meaningful models of vaccine
delivery, rather than those that are simple to model. For example,
assuming that all individuals with HSV-2 infection, a largely undi-
agnosed infection, are instantaneously vaccinated with a therapeu-
tic vaccine at 100% coverage [33], is clearly at odds with the
realities of who would likely be the recipients of a therapeutic
HSV-2 vaccine. The logistics of identifying and reaching suitable
recipients represent practical considerations relevant to all vacci-
nation programs that should be incorporated into future models
of vaccine impact. Efforts are underway to define the preferred
characteristics of HSV vaccines, such as vaccine indications, target
populations, critical efficacy and safety considerations, and perti-
nent vaccination strategies, that would meet priority public health
goals, particularly for low- and middle-income countries [22].
Future models should both incorporate and inform these preferred
product characteristics to optimize their utility to advance devel-
opment and implementation of HSV vaccines with global benefits.
7406 I.H. Spicknall et al. / Vaccine 37 (2019) 7396–7407HSV vaccines have the potential to alleviate a global disease
burden, and vaccine development efforts are well underway
[1,22,51]. Mathematical models take time to develop and fit; there-
fore modeling work should start before there is an approved HSV
vaccine on the market. Models can be updated with efficacy data
for the newest vaccine candidates as they progress through trials.
Previous mathematical models have shown that substantial reduc-
tions in HSV-2 incidence are possible even with an imperfect vac-
cine if the right conditions are met. With the incorporation of the
modeling considerations suggested here, substantial progress
could be made toward understanding the future impact of an
HSV-2 vaccine, which could improve the lives of millions of people
worldwide.
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